For the most up to date information on COVID-19 please visit the Department of Health website. Learn more about how the AIHW is assisting the COVID-19 response and how our other work is affected. Our Covid-19 related resources page includes a list of some existing resources which may be useful when researching issues related to COVID-19.
Australian Institute of Health and Welfare 2019. Gout . Cat. no. PHE259. Canberra: AIHW. Viewed 08 August 2020, https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Australian Institute of Health and Welfare. (2019). Gout . Retrieved from https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Gout . Australian Institute of Health and Welfare, 30 August 2019, https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Australian Institute of Health and Welfare. Gout [Internet]. Canberra: Australian Institute of Health and Welfare, 2019 [cited 2020 Aug. 8]. Available from: https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Australian Institute of Health and Welfare (AIHW) 2019, Gout , viewed 8 August 2020, https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Get citations as an Endnote file:
PDF | 273Kb
Gout is a form of inflammatory arthritis that develops when an excess of uric acid in the blood leads to deposits of uric acid crystals in one or more joints, causing inflammation.
Men are more likely to have gout than women—almost 9 in 10 (87%) people with gout are men
0.8% of Australians had gout in 2017–18, based on self-reported survey data. That is approximately 187,000 people
Gout can be managed or even prevented by long-term therapy with medications and life style changes to control hyperuricaemia and reduce levels of uric acid in the body.
Gout can be controlled with early and ongoing treatment, including:
Flares and complications can be managed by reducing risk factors for hyperuricaemia (dehydration, obesity and alcohol intake), taking urate-lowering medications to keep uric acid levels low, and managing comorbid conditions, such as high blood pressure, chronic kidney disease, diabetes and heart disease.
The use of non-steroidal anti-inflammatory drugs (NSAIDs), low-dose colchicine and oral/intra-muscular/intra-articular glucocorticoids has also been found to be effective in managing acute gout. It has been recommended that people with gout should continue urate-lowering therapy for the rest of their lives .
Data from the AIHW National Hospital Morbidity Database (NHMD) show that, in 2016-17:
Source: AIHW National Hospital Morbidity Database (Data table).
The age-standardised hospitalisation rate for Australians with gout increased between 2005–06 and 2016–17: from 20 hospitalisations per 100,000 population to 28 per 100,000 population. There was a slightly larger increase for females (57%, from 7 to 11 per 100,000 population) compared with males (40%, from 34 to 47 per 100,000 population).
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.